Business Context and Reporting Period
Company: ADC Therapeutics SA
Filing Type: Form 8-K (Current Report)
Date of Report: September 30, 2025
Jurisdiction: Switzerland
Trading Symbol: ADCT (New York Stock Exchange)
This filing serves as a Regulation FD disclosure to make an updated corporate presentation available to investors. The document does not contain audited financial statements or a detailed operational report for a specific fiscal period.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This 8-K filing is limited to the disclosure of an attached corporate presentation (Exhibit 99.1) and does not include numerical financial data within the report body.
Material Changes
No material changes to financial performance or operations are detailed in the text of this filing. The sole reported event is the release of an updated corporate presentation on September 30, 2025.
Guidance, Outlook, and Risks
Management Commentary: The Company made an updated corporate presentation available to the public.
Legal Disclaimer: The information contained in this Item and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Corporate Presentation) for specific financial updates, clinical trial data, or strategic guidance not included in this 8-K text.
- Verify the trading status of ADCT on the New York Stock Exchange.
- Confirm that the corporate presentation has been distributed via the Company's investor relations channels.